F-18 FDG PET/CT Assessment of Gastrointestinal Stromal Tumor Response to Sunitinib Malate TherapyBanzo, Ignacio, MD; Quirce, Remedios, MD; Martinez-Rodriguez, Isabel, MD; Jimenez-Bonilla, Julio, MD; Sainz-Esteban, Aurora, MD; Barragan, Jorge, MD; Portilla-Quattrociocchi, Humberto, MD; Carril, Jose M., MDClinical Nuclear Medicine: March 2008 - Volume 33 - Issue 3 - p 211-212 doi: 10.1097/RLU.0b013e318162dddb Interesting Image Buy Abstract Author InformationAuthors Article MetricsMetrics We report the contribution of F-18 FDG PET/CT in a 49-year-old woman who underwent surgical removal of the ileum for gastrointestinal stromal tumor (GIST) 10 years ago. Four and 2 years ago, peritoneal recurrence and a left liver metastases, respectively, were removed. Despite imatinib mesylate therapy new liver metastases developed. Imatinib was withdrawn and sunitinib malate therapy was started. Serial F-18 FDG PET/CT showed progressive decrease of FDG uptake in 2 hepatic metastases and the normalization of uptake in 2 peritoneal implants. This report describes the value of F-18 FDG PET/CT in GIST treated with the new kit-inhibitor, sunitinib malate. From the Servicio de Medicina Nuclear, HU Marques de Valdecilla, Universidad de Cantabria, Santander, Spain. Received for publication July 19, 2007; revision accepted October 27, 2007. Reprints: Dr. Ignacio Banzo, Servicio de Medicina Nuclear, HU Marques de Valdecilla, Universidad de Cantabria, Av. Valdecilla s/n, 39008 Santander, Spain. E-mail: email@example.com. © 2008 Lippincott Williams & Wilkins, Inc.